Peter Barton Hutt is Director at CONCERT PHARMACEUTICALS, INC. (CNCE). They have made 7 open-market trades across 3 companies since 2010, most recently 2023-03-06.
CIK 0001171527
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 7 sales. Too few scored purchases to measure a record yet.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| CNCE | SELL | 2022-10-14 | 2022-10-18 | $6.09 | $22K | -5.6% | -26.4% | +15.8% |
| MRNA | SELL | 2019-11-20 | 2019-11-22 | $20.18 | $4.0M | -1.2% | -5.7% | -11.3% |
| MRNA | SELL | 2019-09-17 | 2019-09-18 | $17.63 | $1.8M | -10.1% | -16.4% | +4.1% |
| CNCE | SELL | 2019-08-08 | 2019-08-12 | $10.31 | $36K | -3.4% | +6.4% | -32.8% |
| CNCE | SELL | 2016-11-14 | 2016-11-21 | $9.81 | $434K | -13.3% | -7.1% | -4.2% |
| MNTA | SELL | 2014-09-12 | 2014-09-15 | $11.42 | $42K | -10.8% | -2.5% | -2.5% |
| MNTA | SELL | 2010-12-10 | 2010-12-14 | $14.51 | $1.8M | -10.8% | -2.5% | -2.5% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.
| — |
| Total | $46.6M |